E
Evan J. Anderson
Researcher at Emory University
Publications - 283
Citations - 19308
Evan J. Anderson is an academic researcher from Emory University. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 40, co-authored 217 publications receiving 11203 citations. Previous affiliations of Evan J. Anderson include Children's Memorial Hospital & Northwestern University.
Papers
More filters
Journal ArticleDOI
Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older
Patricia L. Winokur,Hana M. El Sahly,Mark J. Mulligan,Sharon E. Frey,Richard E. Rupp,Evan J. Anderson,Kathryn M. Edwards,David I. Bernstein,Kenneth E. Schmader,Lisa A. Jackson,Wilbur H. Chen,Heather Hill,Abigail Bellamy +12 more
TL;DR: In this article, a phase II, randomized, partially-blinded trial was conducted to evaluate the safety and immunogenicity of an MF59-adjuvanted inactivated, split virion, H7N9 influenza vaccine administered at various dose levels and schedules in older adults.
Journal ArticleDOI
Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera.
Binh Ha,Samadhan J. Jadhao,Laila Hussaini,Theda Gibson,Kathy Stephens,Luis Salazar,Caroline Rose Ciric,Meg Taylor,Nadine Rouphael,Srilatha Edupuganti,Christina A. Rostad,S. Mark Tompkins,Evan J. Anderson,Larry J. Anderson +13 more
TL;DR: In this paper, a capture IgM enzyme-linked immunosorbent assay (ELISA) and a companion indirect IgG ELISA for the SARS-CoV-2 spike (S) and nucleocapsid (N) proteins and the receptor-binding domain (RBD) of S were presented.
Journal ArticleDOI
A Retrospective Case-Controlled Study of Rotavirus Vaccine Effectiveness Using Rapid Antigen Testing
Bethany K. Sederdahl,Jumi Yi,Scott Gillespie,Robert C. Jerris,Lars F. Westblade,Andi L. Shane,Colleen S. Kraft,Evan J. Anderson +7 more
Posted ContentDOI
Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial
Angela Branche,Nadine Rouphael,Cecilia Losada,Lindsey R. Baden,Evan J. Anderson,Anne F Luetkemeyer,David Diemert,Patricia L. Winokur,Rachel M. Presti,Angelica Kottkamp,Ann R. Falsey,Sharon E. Frey,Richard E. Rupp,Martin Bäcker,Richard M. Nowak,Emmanuel B. Walter,Lisa A. Jackson,Susan J. Little,Lilly Cheng Immergluck,Siham Mahgoub,Jennifer A. Whitaker,T. Mariya Babu,Paul A. Goepfert,Dahlene N. Fusco,Robert L. Atmar,Christine M. Posavad,Antonia Netzl,Derek J. Smith,Kalyani Telu,Jinjian Mu,Mat Makowski,Mamodikoe Makhene,Sonja Crandon,David C. Montefiori,Paul C. Roberts,John H. Beigel +35 more
TL;DR: In this article , the authors compare early serologic responses from a randomized clinical trial of a second boost with either the Pfizer/BioNTech BNT162b2 (30 mcg dose) Wildtype/Omicron BA.1 or BA.4/5 vaccines against homologous and heterologous strains.
Journal ArticleDOI
Safety and Immunogenicity of Influenza A/H5N8 Virus Vaccine in Healthy Adults: Durability and Cross-reactivity of Antibody Responses.
Kathleen M. Neuzil,Evan J. Anderson,Robert W. Frenck,Sharon E. Frey,Emmanuel B. Walter,Richard E. Rupp,Elizabeth T. Rotrosen,Nadine Rouphael,Rebecca C. Brady,Irene Graham,Kenneth E. Schmader,Laura K. Porterfield,Justin R. Ortiz,Geeta K. Swamy,Hana M. El Sahly,Trushar Jeevan,Ranjan Sitaula,Ashley Wegel,Richard J. Webby,Christopher Bryant +19 more
TL;DR: The authors conducted a phase I, cohort-randomized, double-blind, controlled trial of inactivated influenza A/H5N8 vaccine (clade 2.3.4.4b) administered with or without adjuvant.